

ASX RELEASE**US lung cancer screening expansion investor webinar**

Wellington, NZ, 22 September 2021: [Volpara Health Technologies](#) (“Volpara,” “the Group,” or “the Company”; ASX: VHT), a global health technology software leader providing an integrated breast care platform for the delivery of personalised breast care, will host an investor webinar on **Tuesday 28th September 2021** at 12:00pm NZST (Auckland/Wellington), 9:00am AEST (Sydney/Melbourne) to update shareholders on recent announcements on the Company’s accelerated expansion into the lung cancer screening market in the US.

The call will be hosted by Dr Ralph Highnam PhD, Chief Executive Officer of Volpara Health and Chris Wood, CEO of RevealDx.

Webinar details

Date: Tuesday 28th September 2021

Time: 12:00pm NZST (Auckland/Wellington), 9:00am AEST (Sydney/Melbourne),

To register: https://us02web.zoom.us/webinar/register/WN_gAA5nHMKQlq997g40OXzdQ

Dial in details: Will be provided to you upon registration

Participants will be able to submit questions during the webinar via a written Q&A facility displayed at the bottom of the webinar screen or can submit them in advance to hhowlett@we-worldwide.com.

Authorisation & Additional Information

This announcement was authorised by the Group CEO, Dr Ralph Highnam.

ENDS

For further information, please contact:

Corporate enquiries

Ralph Highnam, CEO
Volpara Health Technologies Ltd
ralph.highnam@volparahealth.com

t: +64 21 149 0541

Investor enquiries

Hannah Howlett
WE Communications
hhowlett@we-worldwide.com

t: +61 450 648 064

Media enquiries

Trevor Chappell
WE Communications
WE-AUVolpara@we-worldwide.com
t: +61 407 933 437

About Volpara Health Technologies Limited (ASX: VHT)

VHT is a health technology software company founded in 2009 on research originally conducted at Oxford University. VHT's clinical functions for screening clinics provide feedback on breast density, compression, dose, and quality, while its enterprise-wide practice-management software helps with productivity, compliance, reimbursement, and patient tracking.

VHT's technology and services have been used by customers and/or research projects in 39 countries and are supported by numerous patents, trademarks, and regulatory clearances, including FDA clearance and CE marking. Since its listing on the ASX in April 2016, VHT has raised A\$132 million, including A\$37 million in April/May 2020 and has made two significant acquisitions in MRS Systems, Inc. (patient tracking software), and CRA Health, LLC (risk and genetics software). VHT is based in Wellington, New Zealand.

For more information, visit www.volparahealth.com